Robert L. Yauch

This study identifies a SWI/SNF-targeting therapy effective against a double-negative prostate cancer subtype, showing it reduces viability in both AR-dependent and WNT-dependent models.

Epiregulon infers single-cell TF activity using ATAC-seq and RNA-seq to predict drug response and identify drivers of cell state.

This paper identifies a potent and specific SMARCA2/A4 degrader, G-6599, which works via FBXO22 recruitment and covalent conjugation, offering therapeutic potential.